Expression of melanin-concentrating hormone (MCH) receptor messenger ribonucleic acid (mRNA) was studied by RT-PCR and Northern blot analysis in human brain; pituitary; adrenal glands; tumor tissues of adrenal tumors, ganglioneuroblastomas, and neuroblastomas; and various cultured tumor cell lines. RT-PCR analysis showed that MCH receptor mRNA was widely expressed in brain tissues, pituitary, normal portions of adrenal glands (cortex and medulla), tumor tissues of adrenocortical tumors (12 of 13 cases), pheochromocytoma (all 7 cases), ganglioneuroblastoma (1 case), neuroblastoma (all 5 cases), and various cultured tumor cell lines (6 of 7 cell lines), including 2 neuroblastoma cell lines. Northern blot analysis showed the expression of MCH receptor mRNA (ϳ2.4 kb) only in the tumor tissues of 5 pheochromocytomas, 1 ganglioneuroblastoma, and 4 neuroblastomas, indicating that the expression levels of MCH receptor mRNA are much higher in these tumors than in the other tissues. These findings raised the possibility that MCH or MCH-like peptides may be related to the pathophysiology of these neural crestderived tumors. (J Clin Endocrinol Metab 86: 369 -374, 2001) M ELANIN-CONCENTRATING hormone (MCH), a cyclic peptide originally isolated from chum salmon pituitaries, induces aggregation of the pigment granules within melanophores of teleost fishes (1). MCH and ␣MSH demonstrate opposite actions on skin coloration in teleost fishes. In mammals including man, MCH is produced mainly in the hypothalamus and acts as a neurotransmitter or a neuromodulator (2-4). MCH is one of the most potent central stimulators of feeding (5, 6). In addition, MCH has various functions in the mammalian central nervous system, such as inhibition of pentylenetetrazole-induced seizure (7), modulation of ACTH and CRH release (8, 9), and effects on behavior (10, 11). Jezova et al. reported that MCH stimulated ACTH secretion, possibly through the release of CRH (8), whereas other investigators reported that MCH decreased ACTH secretion (9), decreased plasma corticosterone levels through an ACTHdependent mechanism (12), or had no effect on the release of CRH and ACTH (13).
M ELANIN-CONCENTRATING hormone (MCH), a
cyclic peptide originally isolated from chum salmon pituitaries, induces aggregation of the pigment granules within melanophores of teleost fishes (1) . MCH and ␣MSH demonstrate opposite actions on skin coloration in teleost fishes. In mammals including man, MCH is produced mainly in the hypothalamus and acts as a neurotransmitter or a neuromodulator (2) (3) (4) . MCH is one of the most potent central stimulators of feeding (5, 6) . In addition, MCH has various functions in the mammalian central nervous system, such as inhibition of pentylenetetrazole-induced seizure (7), modulation of ACTH and CRH release (8, 9) , and effects on behavior (10, 11) . Jezova et al. reported that MCH stimulated ACTH secretion, possibly through the release of CRH (8) , whereas other investigators reported that MCH decreased ACTH secretion (9) , decreased plasma corticosterone levels through an ACTHdependent mechanism (12) , or had no effect on the release of CRH and ACTH (13) .
Several groups recently reported that the orphan G protein-coupled receptor, SLC-1 (14) is the MCH-specific receptor (15) (16) (17) (18) (19) . MCH-binding sites were shown in mouse melanoma cells, rat PC12 pheochromocytomas, human keratinocytes, and other cell lines (20, 21) . MCH reduced slightly corticosterone production induced by ␣MSH in rat adrenal glomerulosa cells (22) . We have recently shown the presence of MCH-specific binding sites in the human brain (23) . MCH receptor (SLC-1) messenger ribonucleic acid (mRNA) was expressed in the human brain, including frontal cortex, amygdala, and midbrain (14) . However, expression of MCH receptor mRNA in adrenal tumors has not been studied. In the present study we therefore investigated the expression of MCH receptor mRNA in human brain; pituitary; adrenal glands; tumor tissues of adrenal tumors, ganglioneuroblastoma, and neuroblastoma; and various tumor cell lines by RT-PCR and Northern blot analysis.
Materials and Methods Tissues
This study was approved by the ethics committee of Tohoku University School of Medicine. Tumor tissues comprising seven benign pheochromocytomas, nine adrenocortical adenomas (four aldosterone-producing adenomas, four cortisol-producing adenomas, and one nonfunctioning ade-noma), four adrenocortical carcinomas, one ganglioneuroblastoma, and five neuroblastomas were obtained at surgery. Morphologically normal portions of adrenal glands were obtained at surgery from four patients with aldosteroneproducing adenoma. Informed consent was obtained from each subject or from the parents of the infant subjects in cases of neuroblastoma and ganglioneuroblastoma. Human brain tissues and pituitaries were obtained at autopsy performed at the Department of Pathology, Tohoku University Hospital, within 4 h postmortem from five patients (two men and three women, 31-70 yr old) after approval by the ethics committee of Tohoku University School of Medicine. These patients had no neurological or endocrinological diseases. The tissues were immediately frozen and stored at Ϫ80 C before extraction of RNA.
Cell culture
T98G human glioblastoma cells, SW-13 human adrenocortical carcinoma cells, DLD-1 human colorectal adenocarcinoma cells, and HeLa human cervical cancer cells were cultured as previously reported (24 -27) . IMR-32 human neuroblastoma cells were obtained from the Cancer Cell Repository, Institute of Development, Aging, and Cancer Tohoku University (Sendai, Japan), and were cultivated at 37 C under 5% CO 2 in MEM supplemented with 10% FBS. BeWo human choriocarcinoma cells were obtained from the Human Science Research Resources Bank of the Japan Health Sciences Foundation (Osaka, Japan) and were cultivated in Ham's F-12 medium supplemented with 15% FBS. NB69 human neuroblastoma cells were obtained from the Riken Cell Bank (Tsukuba, Japan) and were cultivated in RPMI 1640 medium supplemented with 15% FBS.
RT-PCR
Total RNA was extracted from tissues and cultured cells by the guanidine thiocyanate-cesium chloride method. Total RNA (4 g) was denatured at 65 C for 5 min and then transcribed at 37 C for 60 min in a reaction mixture (20 L) containing 0.5 g oligodeoxythymidine, 0.5 mmol/L deoxy-NTP, and 400 U Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc./BRL, Gaithersburg, MD). The reaction was stopped by heating at 95 C for 5 min, diluted with 30 L water, and stored at Ϫ20 C until PCR analysis. One microliter of the reaction mixture was subjected to PCR. The PCR was performed in a total volume of 20 L containing 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCl, 2 mmol/L MgCl 2 , 0.2 mmol/L of each deoxy-NTP, 0.25 mol/L of each primer, and 0.5 U Taq DNA polymerase (Pharmacia Biotech, Piscataway, NJ).
The sense primer was 5Ј-CCTCTGATGGCCCGATAAC-3Ј (nucleotides 60/79), and the antisense primer was 5Ј-GAGAGGTTGATGATGAAGATGTCG-3Ј (complementary to nucleotides 244/267). The nucleotide residues were numbered according to the corrected SLC-1 receptor complementary DNA (cDNA) sequence, with the beginning of the first residue of the ATG triplet encoding the initiative methionine (28) (accession no. Z86090 and U71092). These primers were designed to contain an intron of 1214 bp in the PCR product to differentiate a signal of MCH receptor mRNA (208 bp) from a signal of the primary transcript containing this intron or contaminated genomic DNA. One microliter of water was used instead of the reaction mixture in the negative control. After heating at 96 C for 2 min, denaturation, annealing, and elongation were carried out at 96 C for 20 s, 62 C for 30 s, and 72 C for 90 s, respectively, and the reactions were repeated for 32 cycles, followed by 72 C for 5 min. Amplification products were visualized on a 5% polyacrylamide gel stained with ethidium bromide and viewed on a UV box.
Northern blot analysis
A cDNA fragment for MCH receptor (SLC-1) cDNA was prepared by RT-PCR from human brain mRNA. The sense primer was 5Ј-TCATGATCCACCAGCTCATG-3Ј (nucleotide numbers of the corrected SLC-1 303/322) (28) , and the antisense primer was 5Ј-TCAGCTGTAGCACATAGTAG-3Ј (complementary to nucleotides 896/915).
The amplified cDNA fragment was inserted into the EcoRV site of pBluescript I KS vector (Stratagene, La Jolla, CA), yielding a subclone pBS-hMCHR6. The nucleotide sequence was determined using a 373A Autosequencer (Perkin-Elmer Corp., Chiba, Japan) and was confirmed to be identical to the registered sequence of SLC-1. The entire cDNA insert was isolated by digesting pBS-hMCHR6 with HindIII and EcoRI, whose recognition sites are located in the polylinker sequence of the vector. The resulting HindIII/ EcoRI fragment was labeled with [␣-
32 P]deoxy-CTP by the random priming method and was used as a hybridization probe for MCH receptor mRNA. The XbaI/AccI fragment of pBS-MCH (2) was used as a hybridization probe for MCH mRNA.
Total RNA was extracted from tissues and cultured cells by the guanidine thiocyanate-cesium chloride method and subjected to Northern blot analysis, as previously reported (24 -27) . Radioactive signals were detected by exposing the filters to x-ray films (X-AR5, Eastman Kodak Co., Rochester, NY). The expression of ␤-actin mRNA was examined as an internal control. The probe for ␤-actin mRNA was the SmaI/ ScaI fragment (124/1050) derived from a full-length human ␤-actin cDNA provided by Dr. T. Yamamoto (Gene Research Center, Tohoku University).
Results
RT-PCR analysis showed that MCH receptor mRNA was widely expressed in every region of human brain examined and in the pituitaries. One representative case is shown in Fig. 1A . MCH receptor mRNA was also detected in four normal portions of adrenal gland (cortex and medulla), seven pheochromocytomas (Fig. 1A) , eight of nine adrenocortical adenomas, four adrenocortical carcinomas, one ganglioneuroblastoma (NB2), and five neuroblastomas (NB 1 and NB 3-6; Fig. 1B ). In particular, intense PCR signals of MCH receptor mRNA were observed in all tumor tissues of pheochromocytomas, a ganglioneuroblastoma, and neuroblastomas. MCH receptor mRNA was clearly detected in 10 of 13 adrenocortical tumors. It was weakly detected in adenoma 4 (PA) and carcinoma 4, but not in adenoma 6 (Cushing's syndrome). Thus, MCH receptor mRNA was similarly expressed in both benign adrenocortical adenomas and adre-nocortical carcinomas. There was no apparent difference in the expression of MCH receptor mRNA among aldosteroneproducing adenomas (primary aldosteronism), cortisolproducing adenomas (Cushing's syndrome), and a nonfunctioning adenoma.
MCH receptor mRNA was clearly detected in IMR-32 neu- (Fig. 1, A-C) and may represent PCR products derived from contaminated genomic DNA or the primary transcript containing an intron of 1214 bp. A negative control that used 1 L water instead of cDNA showed no bands (data not shown). ␤-Actin mRNA was similarly expressed in every sample examined (data not shown).
On the other hand, Northern blot analysis showed expression of MCH receptor mRNA only in 5 of 7 pheochromocytomas, 1 ganglioneuroblastoma, and 4 of 5 neuroblastomas ( Fig. 2; negative data in pheo 6 and pheo 7 are not shown). In particular, intense hybridization signals of MCH receptor mRNA were observed in 2 pheochromocytomas (pheo 3 and 4 in Fig. 2 ). The size of the band was 2.4 kb, which is consistent with the previously reported size of SLC-1 mRNA. In addition to the 2.4-kb mRNA, a band of about 3.6 kb was observed in these 2 pheochromocytomas (pheo 3 and pheo 4). Northern blot analysis could not detect MCH receptor mRNA in human brain tissues, pituitary (data not shown), 4 normal portions of adrenal glands (Fig. 2) and 13 tumor tissues of adrenocortical tumors, including 4 aldosteroneproducing adenomas, 4 cortisol-producing adenomas, 1 nonfunctioning adenoma, or 4 adrenocortical carcinomas (only 4 adenomas are shown in Fig. 2 ; other data not shown).
MCH mRNA was detected only in the human hypothalamus, but was not detected in other regions of human brain, pituitaries, adrenal glands, or any of the tumor tissues or cultured tumor cell lines by Northern blot analysis (data not shown).
Discussion
The RT-PCR analysis has shown that MCH receptor mRNA is widely expressed in the human brain tissues; pituitaries; normal adrenal glands; tumor tissues of adrenocortical tumors, pheochromocytoma, ganglioneuroblastoma, and neuroblastoma; and various tumor cell lines. The findings in the Northern blot analysis indicate that the expression levels are particularly high in the tumor tissues of pheochromocytoma, ganglioneuroblastoma, and neuroblastoma. The expression of MCH receptor mRNA in the human brain is consistent with our previous report on MCH-binding sites in the human brain (23) . Kolakowski et al. (14) showed the expression of SLC-1 mRNA (MCH receptor mRNA) in the human brain tissues, including frontal cortex, amygdala, and midbrain, by Northern blot analysis using 5 g polyadenylated RNA. Our negative results in the Northern blot analysis of human brain tissues may be due to the difference in the RNA preparation; 15 g total RNA were used in our Northern blot analysis.
The expression of MCH receptor mRNA in adrenocortical tumors does not seem to be related to the malignancy or the steroid hormone production of the tumors, because it was similarly expressed among aldosterone-producing adenomas, cortisol-producing adenomas, a nonfunctioning adrenocortical adenoma and adrenocortical carcinomas. The high expression in pheochromocytomas, a ganglioneuroblastoma, and neuroblastomas indicates that the MCH receptor is highly expressed in neural crest-derived tumors in both benign tumors (pheochromocytomas) and malignant tumors (ganglioneuroblastomas and neuroblastomas). Consistent with the results of tumor tissues, intense MCH receptor mRNA signals were found in two human neuroblastoma cell lines in the PCR analysis.
In the Northern blot analysis of MCH receptor mRNA, bands of about 3.6 kb were observed in two pheochromo- (28) . On the other hand, the RT-PCR analysis of these two pheochromocytomas (pheo 3 and pheo 4) showed only weak bands of 1.5 kb, which may include both the primary transcript containing this intron and contaminated genomic DNA. Further studies are therefore required to clarify whether the 3.6-kb band in the Northern blot analysis represents the primary transcript of the MCH receptor gene.
It was reported that ␣MSH stimulated aldosterone release from the adrenal zona glomerulosa (29) . POMC peptide fragments, such as ␤MSH and ␥MSH (1-13), inhibited the nicotine-induced release of catecholamines from adrenal chromaffin cells (30) . It is well known that POMC is expressed in the tumor tissues of pheochromocytoma and neuroblastoma (31) . MCH is known to act in a manner opposite to that of ␣MSH in both the skin coloration of teleost fishes and the brain functions of mammals, such as feeding stimulation (12) . It is therefore plausible that MCH receptors expressed in these tumor tissues may mediate the modulatory actions of MCH in tumors, for example, on catecholamine release, in an opposite manner compared with ␣MSH. There was, however, no apparent difference in the clinical data between pheochromocytomas with high MCH receptor mRNA expression (pheo 3 and pheo 4) and the other pheochromocytomas.
Despite the expression of the receptor mRNA, MCH mRNA was not detected in normal adrenal glands or in any of these tumor tissues or cultured tumor cell lines by Northern blot analysis. These findings are consistent with the results of our previous studies, which did not detect immunoreactive MCH in normal adrenal glands or in tumor tissues of pheochromocytomas by the sensitive and specific RIA (2). Immunoreactive MCH was also not detected in tumor tissues of ganglioneuroblastoma and neuroblastoma by RIA (our unpublished observations). These findings indicate that MCH is not likely to be produced in these human peripheral tissues or tumor tissues, at least at biologically active concentrations. On the other hand, Nahon's group reported the expression of MCH peptide and mRNA in rat and human peripheral tissues, including adrenal glands (32) (33) (34) . There was, however, no peak in the position of MCH in reverse phase HPLC analysis of the human peripheral tissues, such as colon and thymus (33) , and about 10 -30% of total immunoreactive MCH eluted in the position of MCH in rat gut extracts (34) . Nahon et al. concluded that immunoreactive MCH in human peripheral tissues may be an intermediate form of the MCH precursor (33) . Thus, there has been no evidence of the production of mature MCH peptide in human peripheral tissues, including adrenal glands. In our previous studies immunoreactive MCH was not detected in human plasma (2) , suggesting that MCH is not likely to act as a circulating hormone in man. The ligand acting on the MCH receptor found in the tumor tissues in the present study, therefore, remains to be determined. It has recently been shown that agouti protein and agouti-related protein act on the melanocortin receptors as antagonists against MSH (35, 36) . We could not deny the possibility that an unidentified MCH-like peptide(s) or related protein(s) may act on MCH receptors expressed in pheochromocytomas, ganglioneuroblastomas, and neuroblastomas.
The present study has shown for the first time the expression of MCH receptor mRNA in the tumor tissues of pheochromocytoma, ganglioneuroblastoma, and neuroblastoma. The expressed MCH receptor may mediate hitherto unknown biological actions of MCH or its unidentified related peptides in these neural crest-derived tumors.
